Kinetic behavior and reversible inhibition of monoamine oxidases-enzymes that many want dead

International Review of Neurobiology

Volumn 100, Issue , 2011, Pages 43-64

  Tipton, Keith F ^a   Davey, Gavin P ^a   McDonald, Andrew G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Amine oxidation; Competitive inhibition; Half life; Mixed inhibition; Noncompetitive inhibition; Steady state kinetics; Tyramine; Uncompetitive inhibition

Indexed keywords

3 PHOSPHOSHIKIMATE 1 CARBOXYVINYLTRANSFERASE; ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIDEPRESSANT AGENT; BROFAROMINE; CLORGYLINE; DOPAMINE; ENZYME INHIBITOR; HARMALINE; LAZABEMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PHENETHYLAMINE; RO 411049; SEROTONIN; TRYPTAMINE; TYRAMINE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING COMPETITION; BOOK; CATALYSIS; COMPETITIVE INHIBITION; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; ENZYME SYNTHESIS; HUMAN; HYDROLYSIS; MICHAELIS MENTEN KINETICS; NONHUMAN; OXYGEN AFFINITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE;

EID: 80053485090     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386467-3.00003-0     Document Type: Chapter

References (71)

1. Anderson M.C., Hasan F., McCrodden J.M., Tipton K.F. Monoamine oxidase inhibitors and the cheese effect. Neurochem. Res. 1993, 18:1145-1149.
2. 14 C] deprenyl. J. Neurochem. 1987, 49:522-527.
3. Baici A. Graphical and statistical analysis of hyperbolic tight-binding inhibition. Biochem. J. 1987, 244:793-796.
4. Binda C., Wang J., Li M., Hubalek F., Mattevi A., Edmondson D.E. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry 2008, 47:5616-5625.
5. Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet 1963, ii:849-851.
6. Bonivento D., Milczek E.M., McDonald G.R., Binda C., Holt A., Edmondson D.E., Mattevi A. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J. Biol. Chem. 2010, 285:36849-36856.
7. Boocock M.R., Coggins J.R. Kinetics of inhibition of 5-enolpyruvylshikimate- 3-phosphate synthase by glyphosate. FEBS Lett. 1983, 154:127-133.
8. Callingham B.A., Mazel P., Porter J.C. Some properties of amine oxidase activities in the rat intestine. Br. J. Pharmacol. 1985, 86:553.
9. Da Prada M., Zürcher G., Würthrich I., Haefely W.E. On tyramine, food beverages and the reversible MAO inhibitor moclobemide. J. Neural Transm. 1988, 26(Suppl.):33-56.
10. Davis D.S., Tasuhara H., Boobis A.R., George C.F. The effects of reversible and irreversible inhibitors of monoamine oxidase on tyramine deamination in dog intestine. Monoamine Oxidase and Disease 1984, 443-448. Academic Press, London. K.F. Tipton, P. Dostert, M. Strolin Benedetti (Eds.).
11. De Colibus L., Li M., Binda C., Lustig A., Edmondson D.E., Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. USA 2005, 102:12684-12689.
12. Della Corte L., Tipton K.F. The turnover of the A- and B-forms of monoamine oxidase in rat liver. Biochem. Pharmacol. 1980, 29:811-815.
13. i . Biochem. J. 1972, 129:197-202.
14. Edmondson D.E., Bhattacharyya A.K., Walker M.C. Spectral and kinetic studies of imine product formation in the oxidation of p-(N,N-dimethylamino)- benzylamine analogues by monoamine oxidase B. Biochemistry 1993, 32:5196-5202.
15. 14 C]-pargyline: a tool for studying the synthesis of the enzyme. Mol. Pharmacol. 1971, 7:219-228.
16. Felner A.E., Waldmeier P.C. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem. Pharmacol. 1979, 28:995-1002.
17. Fierro A., Osorio-Olivares M., Cassels B.K., Edmondson D.E., Sepúlveda-Boza S., Reyes-Parada M. Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg. Med. Chem. 2007, 15:5198-5206.
18. Fischer A.G., Schulz A.R., Oliner L. Thyroidal biosynthesis of iodothyronines. II. General characteristics and purification of mitochondrial monoamine oxidase. Biochim. Biophys. Acta 1968, 159:460-471.
19. Fowler J.S., Volkow N.D., Logan J., Wang G.J., MacGregor R.R., Schlyer D., Wolf A.P., Pappas N., Alexoff D., Shea C. Slow recovery of human brain MAO B after L-deprenyl (Selegiline) withdrawal. Synapse 1994, 18:86-93.
20. Frieden C. Treatment of Enzyme Kinetic Data. I. The effect of modifiers on the kinetic parameters of single substrate enzymes. J. Biol. Chem. 1964, 239:3522-3531.
21. Garel J.R., Labouesse B. Binding interactions between two ligands and a monomeric protein. Study on indole, protons and chymotrypsin. J. Mol. Biol. 1970, 47:41-56.
22. Garrick N.A., Murphy D.L. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 1982, 72:27-33.
23. Green A.R., Mitchell D., Todoff A., Youdim M.B.H. Evidence for dopamine deamination by by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60:343-3429.
24. Hasan F., McCrodden J.M., Kennedy N.P., Tipton K.F. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J. Neural Transm. 1988, 26(Suppl.):1-9.
25. Hearon J.Z., Bernhard S.A., Friess S.L., Botts D.J., Morales M.F. Enzyme Kinetics. The Enzymes 1959, Vol. 1:49-142. Academic Press, New York. 2nd edn.
26. Henderson P.J.F. Steady-state enzyme kinetics with high-affinity substrates or inhibitors. A statistical treatment of dose-response curves. Biochem. J. 1973, 135:101-107.
27. Houslay M.D., Tipton K.F. The reaction pathway of membrane-bound rat liver mitochondrial monoamine oxidase. Biochem. J. 1973, 135:735-750.
28. Houslay M.D., Tipton K.F. A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes. Biochem. J. 1974, 139:645-652.
29. Houslay M.D., Tipton K.F. Amine competition for oxidation by rat liver mitochondrial monoamine oxidase. Biochem. Pharmacol. 1975, 24:627-631.
30. Houslay M.D., Tipton K.F. Rat liver mitochondrial monoamine oxidase. A change in the reaction mechanism on solubilization. Biochem. J. 1975, 145:311-321.
31. Houslay M.D., Garrett N.J., Tipton K.F. Mixed substrate experiments with human brain monoamine oxidase. Biochem. Pharmacol. 1974, 23:1937-1944.
32. Husain M., Edmondson D.E., Singer T.P. Kinetic studies on the catalytic mechanism of liver monoamine oxidase. Biochemistry 1982, 21:595-600.
33. Inoue H., Castagnoli K., Van Der Schyf C., Mabic S., Igarashi K., Castagnoli N. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives. J. Pharmacol. Exp. Ther. 1999, 291:856-864.
34. Krueger M.J., Mazouz F., Ramsay R.R., Milcent R., Singer T.P. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem. Biophys. Res. Commun. 1995, 206:556-562.
35. McDonald A.G., Tipton K.F. Kinetics of catalyzed reactions-biological. Encyclopedia of Catalysis 2002, John Wiley & Sons, New York. http://www.mrw.interscience.wiley.com/enccat/, 10.1002/0471227617.eoc127. I.T. Horváth (Ed.).
36. 2 binding site on human monoamine oxidase-B. Pharmacol. Res. 2010, 62:475-488.
37. Miller J.R., Edmondson D.E. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 1999, 38:13670-13683.
38. Nair N.P., Ahmed S.K., Kin N.M. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J. Psychiatry Neurosci. 1993, 18:214-225.
39. Neff N.H., Goridis C. Neuronal monoamine oxidase: specific enzyme types and their rates of formation. Adv. Biochem. Psychopharmacol. 1972, 5:307-323.
40. 3 H]Harmaline as a specific ligand of MAO A-II. Measurement of the turnover rates of MAO A during ontogenesis in the rat brain. J. Neurochem. 1979, 32:1829-1936.
41. O'Brien E.M., Dostert P., Tipton K.F. Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B. Biochem. Pharmacol. 1995, 50:317-324.
42. Oi S., Yasunobu K.T., Westley J. The effect of pH on the kinetic parameters and mechanism of beef liver monoamine oxidase. Arch. Biochem. Biophys. 1971, 145:557-564.
43. Parkinson D., Lyles G.A., Browne B.J., Callingham B.A. Some factors influencing the metabolism of benzylamine by type A and B monoamine oxidase in rat heart and liver. J. Pharm. Pharmacol. 1980, 32:844-850.
44. Pearce L.B., Roth J.A. Human brain monoamine oxidase type B: mechanism of deamination as probed by steady-state methods. Biochemistry 1985, 24:1821-1826.
45. Pettersson G. Dalziel rate behaviour in ternary-complex mechanisms for enzyme reactions involving two substrates. Biochim. Biophys. Acta 1972, 276:1-11.
46. Pollack S.J., Atack J.R., Knowles M.R., McAllister G., Ragan C.I., Baker R., Fletcher S.R., Iverson L.I., Broughton H.B. Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc. Natl. Acad. Sci. USA 1994, 91:5766-5770.
47. Ramsay R.R. Kinetic mechanism of monoamine oxidase A. Biochemistry 1991, 30:4624-4629.
48. Reid A.A., Hill J.L., Murphy D.L. Interactions of tricyclic antidepressant drugs with human and rat monoamine oxidase type B. Naunyn-Schmied. Arch. Pharmacol. 1988, 388:678-683.
49. Riederer P., Lachenmayer L. Selegiline's neuroprotective capacity revisited. J. Neural Transm. 2003, 110:1273-1278.
50. 3 H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci. 1992, 12:1977-1999.
51. Saura J., Bleuel Z., Ulrich J., Mendelowitsch A., Chen K., Shih J.C., Malherbe P., Da Prada M., Richards J.G. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization. Histochemistry 1996, 70:755-774.
52. Spears G., Sneyd J.G., Loten E.G. A method for deriving kinetic constants for two enzymes acting on the same substrate. Biochem. J. 1971, 125:1149-1151.
53. Strolin Benedetti M., Boucher T., Carlsson A., Fowler C.J. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem. Pharmacol. 1983, 32:47-52.
54. Sullivan J.P., Tipton K.F. Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B. Neurochem. Res. 1992, 8:791-796.
55. Szedlacsek S.E., Duggleby R.G. Kinetics of slow and tight-binding inhibitors. Methods Enzymol. 1995, 249:144-181.
56. Tan A.K., Ramsay R.R. Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase. Biochemistry 1993, 32:2137-2143.
57. Tipton K.F. Mechanism-based inhibitors. Design of Enzyme Inhibitors as Drugs 1989, 70-93. Oxford University Press, Oxford. M. Sandler, H.J. Smith (Eds.).
58. Tipton K.F. Monoamine oxidase inhibitors as antidepressants. Biochemical and Pharmacological Aspects of Depression 1989, 1-24. Taylor & Francis, London. K.F. Tipton, M.B.H. Youdim (Eds.).
59. Tipton K.F. Patterns of enzyme inhibition. EnzymologyLabFax 1996, 115-174. Bios Scientific Publishers and Academic Press, Oxford, UK and San Diego, USA. P.C. Engel (Ed.).
60. Tipton K.F. Inhibitors of monoamine oxidase and the pressor response to dietary amines. Vopr. Med. Khim. 1997, 46:494-503.
61. Tipton K.F. Enzymes: Irreversible Inhibition. Encyclopedia of Life Sciences 2001, John Wiley & Sons, Ltd, Chichester, [doi:10.1038/npg.els.0000601]. http://www.els.net/WileyCDA/, 10.1038/npg.els.0000601. A. Finazzi Agrò (Ed.).
62. Tipton K.F., Fowler C.J. The kinetics of monoamine oxidase inhibitors in relation to their clinical behaviour. Monoamine Oxidase and Disease 1984, 27-40. Academic Press, London. K.F. Tipton, P. Dostert, M. Strolin Benedetti (Eds.).
63. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 1993, 61:1191-1206.
64. Tipton K.F., Balsa D., Unzeta M. Newer approaches to the study of monoamine oxidase inhibition. Monoamine Oxidase: Basic and Clinical Aspects 1993, 1-13. VSP BV, Utrecht, The Netherlands. H. Yashuhara, S.H. Parvez, K. Oguchi, M. Sandler, T. Nagatsu (Eds.).
65. Waldmeier P.C., Felner A.E., Tipton K.F. The monoamine oxidase inhibiting properties of CGP 11305A. Eur. J. Pharmacol. 1983, 94:73-83.
66. Westley A.M., Westley J. Enzyme inhibition in open systems. Superiority of uncompetitive agents. J. Biol. Chem. 1996, 271:5347-5352.
67. Williams J.W., Morrison J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 1979, 63:437-467.
68. Yamada M., Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004, 25:215-221.
69. Youdim M.B.H., Tipton K.F. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8:247-253.
70. Youdim M.B.H., Edmondson D.E., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7:295-309.
71. Yu P.H., Tipton K.F. Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity. Biochem. Pharmacol. 1989, 38:4245-4251.